08:53 AM EDT, 10/08/2024 (MT Newswires) -- Biogen (BIIB) said Tuesday that new data from a phase 2/3 trial of nusinersen support the clinical benefits of a higher dose regimen in treating spinal muscular atrophy in both treatment-naive and previously treated patients.

The investigational higher dose regimen, which includes two 50 mg doses 14 days apart followed by maintenance doses of 28 mg every four months, also showed a 94% reduction in neurodegeneration marker plasma neurofilament light chain, according to the company.

Biogen said it plans to submit applications for the higher dose regimen with global regulatory agencies. Nusinersen, currently marketed as Spinraza, is already approved in over 71 countries at a dosage of 12 mg.

Biogen obtained global rights to develop, manufacture, and market Spinraza from Ionis Pharmaceuticals ( IONS ) .

Price: 184.00, Change: +0.66, Percent Change: +0.36